Low-dose radiation guided by MRD during first treatment for large B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests whether adding low-dose radiation to standard chemoimmunotherapy can improve outcomes for people with newly diagnosed large B-cell lymphoma, using a personalized blood test to guide who gets radiation. It may help reduce the risk of the lymphoma returning by targeting sites still showing signs of disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 19 years old
- You must have newly diagnosed large B-cell lymphoma (including transformed from indolent lymphoma or certain other subtypes)
- You must be planning to receive 6 cycles of standard chemotherapy plus antibody therapy (R-chemoimmunotherapy) as your first treatment, and you may have already had up to one cycle
- You must have a tumor that can be seen on scans (at least 1.5 cm in lymph nodes or 1 cm elsewhere) before starting treatment
- You must have a stored tumor sample from a biopsy that can be used to develop a personalized blood test
- You must not have limited-stage disease (like stage I or II) that would need fewer than 6 cycles, and you must not have lymphoma in the brain or spinal cord
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether using a blood test (ctDNA) can help guide treatment decisions for people with newly diagnosed diffuse large B-cell lymphoma. It tests standard chemotherapy regimens (R-CHOP or R-pola-CHP) and aims to improve outcomes by monitoring tumor DNA in the blood.
This trial tests a new combination of drugs for people with a type of lymphoma called diffuse large B cell lymphoma, especially if you are older or not healthy enough for standard full-dose chemotherapy. The treatment includes two immunotherapy drugs (epcoritamab and polatuzumab) plus a reduced-intensity chemotherapy regimen (mini-CHP). The goal is to see if this combination is safe and effective for people who may not tolerate stronger treatments.
This trial is testing a new combination of drugs for people with a high-risk type of lymphoma called DLBCL who have not been treated before. It adds loncastuximab and roflumilast to the standard R-CHOP therapy to see if it works better at fighting the cancer.
This trial tests a combination of radiation therapy, lenalidomide, and glofitamab for people with a type of lymphoma called DLBCL that has not responded to or has returned after initial treatment. The goal is to see if this combination can help when other treatments have failed.
This trial studies a specific treatment plan to see how well it works for adults with newly diagnosed non-Hodgkin lymphoma that has a high amount of disease. It may help by aiming to control lymphoma more effectively, especially when it is widespread.
This trial studies the best way to use an early (frontline) stem cell transplant for high-risk, CD20-positive diffuse large B-cell lymphoma (DLBCL). It aims to improve outcomes by comparing treatment approaches designed for people with a higher risk score.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.